This method describes high yield in vitro synthesis of both capped and uncapped mRNA from a linearized plasmid containing the Gaussia luciferase (GLuc) gene. The RNA is purified and a fraction of the uncapped RNA is enzymatically capped using the Vaccinia virus capping enzyme. In the final step, the mRNA is transfected into HeLa cells and cell culture supernatants are assayed for luciferase activity.
In vitro transcription is the synthesis of RNA transcripts by RNA polymerase from a linear DNA template containing the corresponding promoter sequence (T7, T3, SP6) and the gene to be transcribed (Figure 1A). A typical transcription reaction consists of the template DNA, RNA polymerase, ribonucleotide triphosphates, RNase inhibitor and buffer containing Mg2+ ions.
Large amounts of high quality RNA are often required for a variety of applications. Use of in vitro transcription has been reported for RNA structure and function studies such as splicing1, RNAi experiments in mammalian cells2, antisense RNA amplification by the “Eberwine method”3, microarray analysis4 and for RNA vaccine studies5. The technique can also be used for producing radiolabeled and dye labeled probes6. Warren, et al. recently reported reprogramming of human cells by transfection with in vitro transcribed capped RNA7. The T7 High Yield RNA Synthesis Kit from New England Biolabs has been designed to synthesize up to 180 μg RNA per 20 μl reaction. RNA of length up to 10kb has been successfully transcribed using this kit. Linearized plasmid DNA, PCR products and synthetic DNA oligonucleotides can be used as templates for transcription as long as they have the T7 promoter sequence upstream of the gene to be transcribed.
Addition of a 5′ end cap structure to the RNA is an important process in eukaryotes. It is essential for RNA stability8, efficient translation9, nuclear transport10 and splicing11. The process involves addition of a 7-methylguanosine cap at the 5′ triphosphate end of the RNA. RNA capping can be carried out post-transcriptionally using capping enzymes or co-transcriptionally using cap analogs. In the enzymatic method, the mRNA is capped using the Vaccinia virus capping enzyme12,13. The enzyme adds on a 7-methylguanosine cap at the 5′ end of the RNA using GTP and S-adenosyl methionine as donors (cap 0 structure). Both methods yield functionally active capped RNA suitable for transfection or other applications14 such as generating viral genomic RNA for reverse-genetic systems15 and crystallographic studies of cap binding proteins such as eIF4E16.
In the method described below, the T7 High Yield RNA Synthesis Kit from NEB is used to synthesize capped and uncapped RNA transcripts of Gaussia luciferase (GLuc) and Cypridina luciferase (CLuc). A portion of the uncapped GLuc RNA is capped using the Vaccinia Capping System (NEB). A linearized plasmid containing the GLuc or CLuc gene and T7 promoter is used as the template DNA. The transcribed RNA is transfected into HeLa cells and cell culture supernatants are assayed for luciferase activity. Capped CLuc RNA is used as the internal control to normalize GLuc expression.
In vitro transcription is a useful method for obtaining high yields of RNA for a variety of applications. The major advantage of using the T7 High Yield RNA Synthesis Kit is that its formulation has been optimized to achieve high yields of RNA. In addition, the reagents provided in the kit are free of contaminating nucleases, resulting in synthesis of high quality, intact RNA transcripts. The kit is designed for high stability and flexibility such that it can be used for synthesizing mRNA, dye labeled RNA, high specific activity radiolabeled probes and capped RNA. The kit manual includes a list of specific protocols and additional materials required for each of these applications. It also includes technical information on using PCR products and synthetic DNA oligonucleotides as templates for transcription. It is important to note that the transcription kit can only utilize DNA templates containing a T7 promoter.
The method described in this article demonstrates post-transcriptional RNA capping using Vaccinia capping enzyme, as well as co-transcriptional capping using RNA cap structure analog. We have shown that both methods synthesize capped RNA that is functionally active post-transfection. The 5′ cap structure improves stability of the RNA and translation efficiency, and hence is important for microinjection11 and transfection7 experiments. The co-transcriptional capping method generates 40-50 μg of ~80% capped RNA. It is important to note that using 3′-0-Me-m7G(5′)ppp(5′)G RNA cap analog (ARCA), which is blocked at the 3′-hydroxyl of the m7G ensures incorporation of the cap in the correct orientation17. To cap larger quantities of RNA it is possible to scale up the standard reactions for both capping methods. However, using the Vaccinia Capping System would be a more feasible option cost-wise since co-transcriptional capping utilizes cap analog, which is a relatively expensive component. The Vaccinia Capping System is also a better method since it has capping efficiency of almost 100%.
The RNA capping methods described above synthesize RNA with a cap 0 structure at the 5′ end. Cap 1 structure involves additional methylation at the 2′-O position of the ribose sugar of the first nucleotide at the ‘ end of the RNA. The cap 1 structure has been reported to enhance RNA translation efficiency18 and can be incorporated by using 2′-O- Methyltransferase20, 21.
The method described in this paper can be used to transcribe, cap and transfect any desired mRNA. The luciferases GLuc and CLuc were specifically used in this protocol due to their many advantages. They are directly secreted into the cell medium, therefore avoiding need for cell lysis. Also, they generate high bioluminescent signal intensity, and the activity assays are highly sensitive and easy to perform. It is important to note that the GLuc expression in the cells can be influenced by various factors other than the functionality of the RNA itself. Some examples are pipetting errors, varying cell numbers per well, transfection efficiency etc. Data normalization is used to account for these factors. In our protocol, we co-transfect CLuc RNA as an internal control with the GLuc RNA. When GLuc luminescence is divided by the CLuc control values, it gets normalized for the errors and variability in transfection19.
The authors have nothing to disclose.
Dongxian Yue, Brett Robb, George Tzertzinis, Tanya Bhatia, Breton Hornblower.
Name of the reagent | Company | Catalogue number | Comments |
T7 High Yield RNA Synthesis Kit | New England Biolabs | E2040S | |
3´-0-Me-m7G(5′)ppp(5′)G RNA Cap Structure Analog | New England Biolabs | S1411S | |
DNase I (RNase-free) | New England Biolabs | M0303S | |
Vaccinia Capping System | New England Biolabs | M2080S | |
MEGAclear Kit | Ambion | AM1908 | |
NanoDrop Spectrophotometer | Thermo Scientific | ||
Agilent RNA 6000 Nano Kit | Agilent Technologies | 5067-1511 | |
Agilent 2100 Bioanalyzer | Agilent Technologies | G2939AA | |
TransIT mRNA Transfection Kit | Mirus Bio LLC | MIR2250 | |
HyClone* Classical Liquid Media: Dulbecco’s Modified Eagle’s Medium, High Glucose | Thermo Scientific | SH30285.01 | |
HyClone Non-essential Amino Acids | Thermo Scientific | SH30238.01 | |
Centro LB 960 | Berthold Technologies | ||
BioLux Gaussia Luciferase Assay Kit | New England Biolabs | E3300S | |
BioLux Cypridina Luciferase Assay Kit | New England Biolabs | E3309S | |
RNase Inhibitor, Murine | New England Biolabs | M0314 | |
RNase Inhibitor, Human Placenta | New England Biolabs | M0307 | |
pCMV-GLuc Control Plasmid | New England Biolabs | N8081 |